公开(公告)号：US20250136706A1

公开(公告)日：2025-05-01

申请号：US18904965

申请日：2024-10-02

Applicant: Novartis AG ,  Emory University ,  The UAB Research Foundation

Inventor： Guido JUNGE ,  James RUSH ,  Andrew B. ADAMS ,  Alfred Joseph TECTOR, III

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P37/06 ,  C07K16/18 ,  C07K16/36

Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

公开(公告)号：US20240277689A1

公开(公告)日：2024-08-22

申请号：US18569432

申请日：2022-06-17

Applicant: Novartis AG

Inventor： Raghav CHAWLA ,  Thomas HOLBRO ,  Guido JUNGE ,  Anna Svenja SCHUBART WELLENSIEK

IPC: A61K31/454

CPC classification number: A61K31/454

Abstract: Described herein are methods of treating an autoimmune benign hematological disorder (e.g., ITP, CAD, wAIHA, and TTP) with the Factor B inhibitor LNP023 (iptacopan) or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.

公开(公告)号：US20230203176A1

公开(公告)日：2023-06-29

申请号：US17946917

申请日：2022-09-16

Applicant: Novartis AG ,  Emory University ,  The UAB Research Foundation

Inventor： Guido JUNGE ,  James RUSH ,  Andrew B. ADAMS ,  Alfred Joseph TECTOR, III

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  C07K16/18 ,  A61P37/06

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/18 ,  A61P37/06 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/56 ,  A61K2039/545

Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

公开(公告)号：US20220177569A1

公开(公告)日：2022-06-09

申请号：US17455192

申请日：2021-11-16

Applicant: NOVARTIS AG

Inventor： Guido JUNGE ,  Michael KIFFE ,  Jiri KOVARIK ,  Richard STEIN ,  Frank WALDRON-LYNCH

IPC: C07K16/24 ,  C07K16/28 ,  C07K16/46 ,  A61K45/06 ,  A61P37/00

Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of an NLRC4 inflammasomopathy, such as an NLRC4-GOF inflammasomopathy in a subject in need thereof. This invention also relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof for use in the treatment or for use in alleviating the symptoms of AIFEC in a subject in need thereof.

公开(公告)号：US20240309084A1

公开(公告)日：2024-09-19

申请号：US18272702

申请日：2022-01-18

Applicant: Novartis AG

Inventor： Martin ALLAN ,  Jeffrey BAGDANOFF ,  David Weninger BARNES ,  John BLANKENSHIP ,  James BRADNER ,  Kevin CLAIRMONT ,  Brian GRANDA ,  Guido JUNGE ,  Thomas SMITH ,  Elisabetta TRAGGIAI ,  Max WARNCKE

IPC: C07K16/28 ,  A61K47/54 ,  A61K47/68 ,  C07K16/40

CPC classification number: C07K16/28 ,  A61K47/549 ,  A61K47/6849 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/62 ,  C07K2317/70

Abstract: The present disclosure features bifunctional compounds for the degradation of extracellular targets, as well as compositions and related methods thereof.

公开(公告)号：US20220356455A1

公开(公告)日：2022-11-10

申请号：US17261533

申请日：2019-07-17

Applicant: NOVARTIS AG

Inventor： Agostino CIRILLO ,  Hilmar EBERSBACH ,  Boerje HARALDSSON ,  Thomas HUBER ,  Guido JUNGE ,  Regina LINK ,  Max WARNCKE ,  Chao ZOU

IPC: C12N9/14 ,  A61K45/06

Abstract: The invention relates to design and therapeutic use of solubilized apyrase polypeptides, pharmaceuticals compositions, therapeutic uses and methods useful for preventing and treating tissue damage.